Shares of Fortress Biotech Inc. (NASDAQ:FBIO) shot up 7.3% during mid-day trading on Tuesday . The stock traded as high as $2.84 and last traded at $2.81, with a volume of 116,576 shares. The stock had previously closed at $2.62.

Separately, FBR & Co reissued an “outperform” rating on shares of Fortress Biotech in a report on Wednesday, July 20th.

The firm’s market cap is $136.76 million. The firm’s 50 day moving average is $2.76 and its 200 day moving average is $2.98.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/fortress-biotech-inc-fbio-shares-up-7-3.html

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.02. Fortress Biotech had a negative return on equity of 79.62% and a negative net margin of 1,687.06%. On average, analysts expect that Fortress Biotech Inc. will post ($1.03) earnings per share for the current fiscal year.

In other news, SVP George Avgerinos sold 48,912 shares of Fortress Biotech stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $2.55, for a total value of $124,725.60. Following the transaction, the senior vice president now directly owns 293,000 shares in the company, valued at $747,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 31.54% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC raised its position in Fortress Biotech by 0.6% in the second quarter. Parametric Portfolio Associates LLC now owns 57,196 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 344 shares during the last quarter. ClariVest Asset Management LLC raised its position in shares of Fortress Biotech by 53.6% in the second quarter. ClariVest Asset Management LLC now owns 117,719 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 41,100 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Fortress Biotech by 369.1% in the first quarter. Goldman Sachs Group Inc. now owns 57,548 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 45,280 shares in the last quarter. Landscape Capital Management L.L.C. raised its position in shares of Fortress Biotech by 208.0% in the first quarter. Landscape Capital Management L.L.C. now owns 69,290 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 46,790 shares in the last quarter. Finally, Teachers Advisors Inc. purchased a new position in shares of Fortress Biotech during the second quarter valued at about $146,000. Institutional investors and hedge funds own 16.67% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

5 Day Chart for NASDAQ:FBIO

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.